Background Alteplase is effective for treatment of acute ischaemic stroke but debate continues
about its use after longer times since stroke onset, in older patients, and among patients …

Stroke remains the second-leading cause of death and the third-leading cause of death and
disability combined (as expressed by disability-adjusted life-years lost – DALYs) in the world…

Methods A hybrid approach based on established processes described by Glaser15 and by
the National Institutes of Health (http://prevention. nih. gov/cdp/about. aspx) 16 was used to …

Background Among patients with acute ischemic stroke due to occlusions in the proximal
anterior intracranial circulation, less than 40% regain functional independence when treated …

Background The use of warfarin reduces the rate of ischemic stroke in patients with atrial
fibrillation but requires frequent monitoring and dose adjustment. Rivaroxaban, an oral factor …

Background Dual antiplatelet therapy with clopidogrel plus low-dose aspirin has not been
studied in a broad population of patients at high risk for atherothrombotic events. Methods We …

Background Early administration of intravenous recombinant tissue plasminogen activator (rt-PA)
after ischaemic stroke improves outcome. Previous analysis of combined data from …

Background Intravenous thrombolysis with alteplase is the only approved treatment for acute
ischemic stroke, but its efficacy and safety when administered more than 3 hours after the …

Background Thrombolysis for acute ischaemic stroke has been investigated in several
clinical trials, with variable results. We have assessed the safety and efficacy of intravenous …

… Hacke W. Thrombolytic therapy in acute ischemic stroke: an update. … von Kummer R,
Hacke W. Safety and efficacy of intravenous tissue plasminogen activator and heparin in acute …